Results 181 to 190 of about 2,911,119 (244)

Actionable mutations in pancreatic cancer: where targeted therapies are making a difference. [PDF]

BMJ Open Gastroenterol
Fivaz M, Bornand A, Corro C, Koessler T, Genoud V.   +4 more
europepmc   +1 more source

Infantile Fibrosarcoma of the Hand: Limb-Sparing Treatment With Modern Targeted Oral Chemotherapy and Conservative Surgical Resection. [PDF]

J Hand Surg Glob Online
Vaile JR, Tipps JA, Hurley R, Struble SL, Allen BE, Surrey LF, Finn LS, Balis FM, Laetsch TW, Mendenhall SD.   +9 more
europepmc   +1 more source

Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How? [PDF]

J Gastrointest Cancer
Barsch M, Dopfer EP, Schultheis AM, Quante M.   +3 more
europepmc   +1 more source

Small-Molecule Trk Agonists: Where Do We Go from Here? [PDF]

J Med Chem
Thompson TS, Sefiani A, Burgess K.
europepmc   +1 more source

BDNF and miRNAs in acupuncture-regulated neuroplasticity: Emerging mechanisms and therapeutic strategies. [PDF]

Medicine (Baltimore)
Li J, Liu L, Sun S, Liu C, Yin P.
europepmc   +1 more source

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment. [PDF]

Pharmaceut Med
Kong L, Grobman B, Mansur A, Lee A, Bondarchuk C, Erdogan H, Lu CY.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

China special issue on gastrointestinal tumors—NTRK fusion in a large real‐world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment

International Journal of Cancer, 2023
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers and targets of TRK inhibitors in solid tumors. Little is known about NTRK fusion in Chinese patients with pan‐cancer.
C. Qi, Ting Zhou, Yue-zong Bai, Hui Chen, Jiajia Yuan, Feilong Zhao, Chang Liu, Mingyang Ma, Ting Bei, Shiqing Chen, Xiaochen Zhao, Chun-Cheng R. Chen, L. Shen   +12 more
semanticscholar   +1 more source

Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.

Journal of Medicinal Chemistry, 2022
Kinase fusions involving tropomyosin receptor kinases (TRKs) have been proven to act as strong oncogenic drivers and are therefore recognized as attractive therapeutic targets. We screened an in-house kinase-focused library and identified a promising hit
Toshiya Ito, Kazutomo Kinoshita, Masaki Tomizawa, Shojiro Shinohara, Hiroki Nishii, M. Matsushita, K. Hattori, Y. Kohchi, M. Kohchi, T. Hayase, Fumio Watanabe, K. Hasegawa, Hiroshi Tanaka, Shino Kuramoto, Kenji Takanashi, N. Oikawa   +15 more
semanticscholar   +1 more source

Abstract 6187: ICP-723 is a potent pan-TRK Inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations of NTRK fusions

Cancer Research, 2022
Background: Somatic oncogenic fusions of NTRK with other genes, such as ETV6, LMNA, TPM3, PAN3, etc. occur in a wide range of adult and pediatric tumors.
Ruixia Liang, Chao Zhou, Yingrui Han, P. Lu, Charles Ying Wang, Zuopeng Wang, Richard Liu, Norman Kong, Jason Zhang, J. J. Cui, D. Ouyang   +10 more
semanticscholar   +1 more source